Cell therapy

Cell Therapy

Path 41 Leveraging and enhancing the inherent potentially therapeutic properties of mesenchymal cells, Bonus Biogroup is developing investigational therapies designed to control inflammation and promote tissue regeneration in different settings.
Path 42

Cell Therapy

Path 41 Leveraging and reinforcing the natural ability of adipose mesenchymal stromal cells to regulate the immune system, Bonus BioGroup is developing an array of cell-based and cell-free technologies to control inflammation in different settings.
Path 42

Every year, millions of patients suffer from life-threatening or debilitating conditions that involve an uncontrolled overreaction of the immune system, such as ARDS, SEPSIS, and autoimmune and rheumatological diseases.

Therapies consisting of living cells are potentially able to deploy multiple factors with possible therapeutic effects.

Adipose-derived mesenchymal stem cells have been widely studied for their potential biological functions:

Immunomodulatory, anti-inflammatory, and support tissue regeneration (Caplan, 2017; Dominici et al., 2006; Galipeau & Sensebé, 2018)
Potential for autologous use, where MSCs can be isolated from a patient and expanded for regenerative applications requiring long-term cell persistence (Pittenger et al., 2019; FDA HCT/Ps Guidance)
Can be produced from healthy donor, banked, and expanded for allogeneic applications as a ready-to-use therapy (Sensebé & Bourin, 2009; EMA ATMP Guidance)

Adipose-derived mesenchymal stem cells have been widely studied for their potential biological functions:

Immunomodulatory, anti-inflammatory, and support tissue regeneration (Caplan, 2017; Dominici et al., 2006; Galipeau & Sensebé, 2018)

Potential for autologous use, where MSCs can be isolated from a patient and expanded for regenerative applications requiring long-term cell persistence (Pittenger et al., 2019; FDA HCT/Ps Guidance)

Can be produced from healthy donor, banked, and expanded for allogeneic applications as a ready-to-use therapy (Sensebé & Bourin, 2009; EMA ATMP Guidance)

MesenCure is an advanced allogeneic cell therapy product candidate designed to overcome cell therapy limitations in treating inflammation and tissue damage, with a lead indication in respiratory distress, including all-cause ARDS.

A proprietary composition of matter comprising cells with enhanced therapeutic capacity designed to overcome the historical challenges in MSC therapy for ARDS.

Up to 70K patients can be treated from a single donor cell bank without exceeding 20 population doublings, maintaining a youthful and potent cell culture.

Completed in Israel a multi-center Phase II study for treating severely ill patients affected by respiratory distress due to COVID-19 pneumonia.

Demonstrated potential in preclinical models for treating respiratory distress caused by biological and chemical agents, as well as non-pulmonary diseases involving inflammation and tissue damage.

Harnessing nature, Bonus Biogroup is committed to researching and developing novel tissue engineering and cell therapy solutions to address unmet clinical needs and support patients in living longer, healthier lives.